CR Shuanghe submits the application for import registration of Korean LG life DPP-IV hypoglycemic drug lc-15-0444

South Korean LG new hypoglycemic drug distributed by China Resources Shuanghe has submitted an application for registration of imported drugs This product is a DPP-IV inhibitor product, and its similar products are launched in China by bringer Ingelheim Lilly In 2010, China Resources Shuanghe signed an exclusive agreement with LG Life Science Co., Ltd of South Korea Shuanghe exclusively licensed and distributed lc-15-0444 of LG life in China After the product registration, it will exclusively import and sell lc-15-0444 products In addition, Hengrui pharmaceutical related products have started clinical trials in the United States Ddp-iv inhibitor not only has the effect of promoting insulin secretion, but also has the advantages of reducing hypoglycemia and not gaining weight Since the first product was launched in 2006, the sales volume has increased rapidly Us professional organizations predict that the global market of DPP-IV inhibitor products will exceed 7 billion US dollars in 2015 The data shows that the prevalence of diabetes in men and women over 20 years old in China has reached 10.6% and 8.8% respectively, and the overall prevalence rate has reached 9.7% At the same time, the prevalence rate of pre diabetes is as high as 15.5%, and the market for diabetes reduction is broad At present, China Resources Shuanghe has three major hypoglycemic drugs, i.e Gliquidone, metformin and pioglitazone The implementation of DPP-IV product cooperation between China Resources Shuanghe and Korean LG company will enrich the company's product line of hypoglycemic drugs, help the company to break the bottleneck of product growth, enhance the company's new product development strength, seek long-term development of hypoglycemic drug market, and make the hypoglycemic drugs bigger and stronger.